Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1996 1
1997 3
1998 3
1999 5
2000 2
2001 5
2002 3
2003 4
2004 2
2005 3
2006 5
2007 2
2008 1
2009 4
2010 7
2011 8
2012 4
2013 4
2014 5
2015 6
2016 1
2017 2
2018 1
2019 1
2020 6
2021 2
2023 2
2024 2
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.
Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Martinez E, Roa JC, Diggs MR, Fulda ES, Paradis K, Wiviott SD, Foldyna B, Looby SE, Desvigne-Nickens P, Alston-Smith B, Leon-Cruz J, McCallum S, Hoffmann U, Lu MT, Ribaudo HJ, Douglas PS; REPRIEVE Investigators. Grinspoon SK, et al. N Engl J Med. 2023 Aug 24;389(8):687-699. doi: 10.1056/NEJMoa2304146. Epub 2023 Jul 23. N Engl J Med. 2023. Update in: N Engl J Med. 2024 May 2;390(17):1626-1628. doi: 10.1056/NEJMc2400870. PMID: 37486775 Free PMC article. Updated. Clinical Trial.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial.
Lu MT, Ribaudo H, Foldyna B, Zanni MV, Mayrhofer T, Karady J, Taron J, Fitch KV, McCallum S, Burdo TH, Paradis K, Hedgire SS, Meyersohn NM, DeFilippi C, Malvestutto CD, Sturniolo A, Diggs M, Siminski S, Bloomfield GS, Alston-Smith B, Desvigne-Nickens P, Overton ET, Currier JS, Aberg JA, Fichtenbaum CJ, Hoffmann U, Douglas PS, Grinspoon SK; REPRIEVE Trial Writing Group. Lu MT, et al. JAMA Cardiol. 2024 Apr 1;9(4):323-334. doi: 10.1001/jamacardio.2023.5661. JAMA Cardiol. 2024. PMID: 38381407 Free PMC article.
Indinavir nephropathy.
Tashima KT, Horowitz JD, Rosen S. Tashima KT, et al. N Engl J Med. 1997 Jan 9;336(2):138-40. doi: 10.1056/NEJM199701093360215. N Engl J Med. 1997. PMID: 8992346 No abstract available.
Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV.
Erlandson KM, Orkaby AR, Umbleja T, Ribaudo HJ, Brown TT, Zanni MV, Diggs MR, Chu SM, Fitch KV, Fichtenbaum CJ, Malvestutto C, Aberg JA, Bloomfield GS, Currier JS, Tashima KT, de Lacerda MVG, Heath SL, Lu MT, Landay A, Kuchel GA, Douglas PS, Grinspoon SK. Erlandson KM, et al. Among authors: tashima kt. JACC Adv. 2025 Sep;4(9):102077. doi: 10.1016/j.jacadv.2025.102077. Epub 2025 Aug 20. JACC Adv. 2025. PMID: 40839903 Free article.
Retreatment of Hepatitis C Virus Among People Who Inject Drugs.
Thomas AM, Litwin AH, Tsui JI, Sprecht-Walsh S, Blalock KL, Tashima KT, Lum PJ, Feinberg J, Page K, Mehta SH, Kim AY, Norton BL, Heo M, Stein ES, Murray-Krezan C, Arnsten J, Groome M, Waters E, Taylor LE. Thomas AM, et al. Among authors: tashima kt. Clin Infect Dis. 2025 Apr 15:ciaf082. doi: 10.1093/cid/ciaf082. Online ahead of print. Clin Infect Dis. 2025. PMID: 40230037
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis.
Fichtenbaum CJ, Malvestutto CD, Watanabe MG, Davies Smith E, Ribaudo HJ, McCallum S, Fitch KV, Currier JS, Diggs MR, Chu SM, Aberg JA, Lu MT, Valencia J, Gómez-Ayerbe C, Brar I, Valdez Madruga J, Bloomfield GS, Douglas PS, Zanni MV, Grinspoon SK; REPRIEVE Investigators. Fichtenbaum CJ, et al. Lancet HIV. 2025 Jul;12(7):e496-e505. doi: 10.1016/S2352-3018(25)00043-8. Epub 2025 Jun 4. Lancet HIV. 2025. PMID: 40482662 Clinical Trial.
Diagnosis of acute HIV infection: it's time to get moving!
Flanigan T, Tashima KT. Flanigan T, et al. Among authors: tashima kt. Ann Intern Med. 2001 Jan 2;134(1):75-7. doi: 10.7326/0003-4819-134-1-200101020-00017. Ann Intern Med. 2001. PMID: 11187423 No abstract available.
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A; GS-US-540-5773 Investigators. Goldman JD, et al. Among authors: tashima kt. N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27. N Engl J Med. 2020. PMID: 32459919 Free PMC article. Clinical Trial.
93 results